These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2284531)

  • 1. When does superficial bladder cancer resist intravesical therapy?
    Vögeli T; Ackermann R
    Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 3. Is intravesical chemotherapy for superficial bladder cancer still justified?
    Okeke AA; Probert JL; Gillatt DA; Schwaibold H
    BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
    [No Abstract]   [Full Text] [Related]  

  • 4. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
    Bouffioux C
    Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
    [No Abstract]   [Full Text] [Related]  

  • 10. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
    Hardeman SW; Perry A; Soloway MS
    J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy for superficial bladder cancer.
    Baselli EC; Greenberg RE
    Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions).
    Bouffioux C; van der Meijden A; Kurth KH; Jakse G; Bono A; Hall R; Oosterlinck W; Sylvester R
    Prog Clin Biol Res; 1992; 378():29-42. PubMed ID: 1301584
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravesical and systemic chemotherapy of murine bladder cancer.
    Soloway MS
    Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
    [No Abstract]   [Full Text] [Related]  

  • 15. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
    van der Meijden AP
    Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk-adapted use of intravesical chemotherapy.
    Lerner SP; Au JL
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.